At ultraconserved sites, EvoD led to large reductions in the FPR: 55% for Condel and 41% for PolyPhen-2. We retrieved the population allele frequency of the neutral HumVar nSNVs at ultraconserved sites from a 5,400-exome data set 4 and found that EvoD improved diagnoses across the spectrum of rare (<0.1%) to common (>5%) alleles (Fig. 1a) . The balanced accuracy of EvoD was also significantly higher than that of Condel and PolyPhen-2 at ultraconserved sites ( Table 1 ; P < 10 -10 ). Furthermore, EvoD's performance was consistent across ultra-, well-and less-conserved sites, whereas Condel and PolyPhen-2 showed uneven performance across these classes ( Table 1) .
For each nSNV, the EvoD statistical model also produced an impact score that reflected the degree of neutrality: most neutral = 0 and most non-neutral = 100. In an analysis of 244,272 nSNVs from the 1000 Genomes Project, we found that the population frequency of nSNVs decayed with increasing impact score (Fig. 1b) . We therefore used the empirical distribution of EvoD scores to determine the statistical significance of a neutral or non-neutral diagnosis (P value) adaptively for variants at ultra-, well-and less-conserved sites (Supplementary Fig. 2 ).
Using EvoD, we analyzed nSNVs in an example set of eight personal HapMap exomes 5 containing a total of 13,372 nSNVs at ultraconserved sites. Of these, 4% were predicted to be non-neutral (P < 0.05). An overwhelming majority (94%) of these non-neutral nSNVs were found in heterozygous genotypes that would neutralize the negative effects of recessive alleles. Similar results were observed for 35,367 nSNVs at well-and less-conserved sites, which were also reflected in the neutrality heat maps showing the EvoD impact scores of nSNVs in heterozygous genotypes (Fig. 1c) . In contrast, the fraction of homozygous nSNVs with high EvoD impact scores was much smaller at ultraconserved sites (Fig. 1c) . EvoD predicted no more than one homozygous nSNV per exome to be non-neutral (P < 0.05) in ultraconserved sites, which is consistent with the fact that individuals contributing to HapMap sequencing do not suffer from any known Mendelian disease.
Our results show that an evolution-aware approach to training and testing computational tools leads to better functional predictions for nSNVs, particularly at the most functionally important positions. Evol. consv., evolutionary conservation category; TPR, true positive rate (sensitivity); FPR, false positive rate; TNR, true negative rate (specificity); FNR, false negative rate; BAcc, balanced accuracy; MCC, Matthews correlation coefficient 6 .
neonatal desensitization does not universally prevent xenograft rejection
To the Editor: Human cells transplanted into immunocompetent animals are generally rejected within 2-4 weeks 1 . Severe immune suppression is capable of protecting the grafted cells; however, such treatment is associated with unacceptable side effects 2 . An important advancement in the field was the introduction of immunodeficient animal models that accept xenografts, but these are poor models for human diseases 3 . A paper published in Nature Methods proposed neonatal desensitization without an overall suppression of the immune system 4 as an alternative. Encouraged by this study, we attempted to use neonatal desensitization to protect grafts of two types of human cells in mice and rats (Fig. 1) . The experiments were conducted in two independent laboratories.
The first cell type we tested was immortalized, luciferaseexpressing human glial-restricted precursor (hGRP) cells derived from fetal brain (Q Therapeutics). We induced neonatal desensitization by intraperitoneal injection of 1 × 10 5 hGRP cells into BALB/c mice. The experiment was repeated three times using a total of 37 mice (Supplementary Methods). hGRPs initially npg nature methods | VOL.9 NO.9 | SEPTEMBER 2012 | 857 correspondence human cells. Although this method may work for some specific cell types, such as those reported by Kelly et al., our studies show that the method is unfortunately not universal. To date, no other group has confirmed the efficacy of neonatal desensitization to our knowledge. In fact, the induction of host tolerance by exposure to xenogeneic antigens, even within the neonatal period, is counterintuitive. This approach is one of the principles of vaccination at birth (as with the human Bacillus Calmette-Guérin (BCG) vaccine) and leads to stimulation of an immune response rather than tolerance. Indeed, studies on organ transplantation have revealed that neonatal inoculation with allogeneic cells leads to allograft tolerance, whereas neonatal inoculation with xenogeneic cells results in rejection of xenografts 5 . Long-term tolerance to allografts has been shown to correlate well with chimerism, that is, the prolonged survival of the cells used for neonatal desensitization 6 . In our studies, instead of a long-term chimerism, we observed rapid loss of the cells used for desensitization. All together, neonatal desensitization has not proven to be the 'holy grail' for preclinical cell transplantation investigations, and the problem of tolerance induction to human xenografts remains unresolved. produced a strong bioluminescence imaging (BLI) signal; but a dramatic loss of signal was observed within a few days, indicating rapid elimination of transplanted cells in the neonates (Fig. 1a) . Once the desensitized animals reached maturity, 3 × 10 5 hGRP cells were injected into the brain parenchyma; parallel transplantations were conducted in nondesensitized littermates as controls. We monitored the survival of transplanted cells via BLI. Initially, transplanted hGRPs produced a strong BLI signal, which denoted robust survival. However, the signal gradually decreased over time and was undetectable after 2 weeks (Fig. 1b) . We observed no difference in the time course of signal loss between desensitized and control animals.
To validate the BLI results, we performed immunohistochemistry for the human-specific marker HuNu (Fig. 1c) and luciferase (Fig. 1d) on the brain sections of animals that had received human cell transplants. The transplantation site could be easily identified by the area of focal CD45 + immune-cell infiltration. The intensity of this infiltration was similar in desensitized (Supplementary Fig. 1a ) and control ( Supplementary Fig. 1b) animals. Quantification of fluorescence signal for both groups did not show any significant difference (Fig. 1g) . hGRP cells transplanted into rag2 -/-immunodeficient mice (n = 5 mice, in parallel with the last cohort of desensitized mice) survived well for several weeks (Fig. 1e) .
The second cell type we tested was a nontransformed neural stem cell line derived from human umbilical cord blood (HUCB-NSC). We induced neonatal desensitization by intraperitoneal injection of 1 × 10 5 HUCB-NSC cells into Wistar rats (five independent experiments with a total of 35 rats). We transplanted 2 × 10 5 HUCB-NSC cells into the brain of 6-week-old animals (desensitized or controls), which were then killed at different time points (1, 3, 7, 14 and 21 d after transplantation) for histological detection of cell survival using immunohistochemistry against a human-specific marker. We detected many human cells 1 and 3 d after transplantation (Fig. 1h,i) , but this number decreased substantially at later time points (7 and 14 d) (Fig. 1j,k) . Almost no cells were detectable at day 21 (Fig. 1l) . We confirmed good survival of HUCB-NSC cells in rag2 -/-mice (Fig. 1f) . Although some immunodeficient rats are available, rag2 -/-mice are known to be superior in accepting cellular grafts and were therefore used as the control in our rat experiments. The longest follow-up of grafted HUCB-NSC cells in rag2 -/-mice was 5 weeks.
In our hands, the neonatal desensitization method failed to induce specific tolerance of the recipient animals to transplanted Days post grafting h i j k l npg required for robust application of the model. To this end, a systematic characterization will be required to evaluate the following issues: the number and types of cells and route of administration that can induce neonatal desensitization; the number of cells for adult CNS grafting and required degree of similarity to the inoculating cells; the mechanism of desensitization, including the fate of desensitizing cells after inoculation in the neonate; the features of the host environment that permit desensitization and/or enhance rejection; and the specific donor-host species pairings that facilitate or inhibit desensitization. We are actively pursuing some of these questions. For example, for successful transplantation in the mouse, it is necessary to significantly increase the number of inoculating cells beyond that used for transplant in rats (V.R. et al., unpublished data). Fully understanding the mechanisms underlying this phenomenon, and defining its practical limits, is a larger task than can be undertaken by one group. In this respect, we would like to emphasize that it is critical for such work that careful attention is paid to the appropriate use of positive controls. In particular, there must be demonstration that the cells grafted into the adult brain of an animal that has undergone neonatal desensitization are capable of surviving for the same period of time using another effective immunosuppression regime in the same animal model. 
